더바이오 10월 13일 주요뉴스 [https://www.thebionews.net/edit/webzine.html?idxno=661](https://www.thebionews.net/edit/webzine.html?idxno=661) ●한미약품 ‘에페’ 허가에 ‘K비만약’ 경쟁 본격화…후발주자 ‘효능·제형’ 차별화 [https://www.thebionews.net/news/articleView.html?idxno=28945](https://www.thebionews.net/news/articleView.html?idxno=28945) ●새판짜기 나선 노보…넥스트 위고비·마운자로는 무엇? [https://www.thebionews.net/news/articleView.html?idxno=28947](https://www.thebionews.net/news/articleView.html?idxno=28947) ●기술수출 넘어 ‘뉴코·공동개발’…中바이오가 전한 신약 개발 협력 성공과 실패 [https://www.thebionews.net/news/articleView.html?idxno=28946](https://www.thebionews.net/news/articleView.html?idxno=28946) ●큐리언트, 론자와 ‘CDK7 저해제’ 독점 L/O…이중 페이로드 ADC 사업 확대 [https://www.thebionews.net/news/articleView.html?idxno=28949](https://www.thebionews.net/news/articleView.html?idxno=28949) ●에이피트바이오, 마더스제약에 L1CAM 타깃 'ADC용 항체' L/O…선급금 26.5억원 [https://www.thebionews.net/news/articleView.html?idxno=28970](https://www.thebionews.net/news/articleView.html?idxno=28970) ●조병철 교수 “제2 렉라자 탄생하려면 임상 수행 넘어 신약 개발 주도해야” [https://www.thebionews.net/news/articleView.html?idxno=28965](https://www.thebionews.net/news/articleView.html?idxno=28965) ●노연홍 제약바이오협회장 “AI·데이터 기반 글로벌 임상 혁신 허브 구축해야” [https://www.thebionews.net/news/articleView.html?idxno=28969](https://www.thebionews.net/news/articleView.html?idxno=28969) ●강석모 상무 “동물대체시험법, 새 규제장벽 될 수도…비임상 전략 재정비해야” [https://www.thebionews.net/news/articleView.html?idxno=28976](https://www.thebionews.net/news/articleView.html?idxno=28976) ●티움바이오, ‘토스포서팁’ 4년만에 후기 임상 눈앞…“장기 치료 효과가 관건” [https://www.thebionews.net/news/articleView.html?idxno=28975](https://www.thebionews.net/news/articleView.html?idxno=28975) ●삼성바이오, 폴리펩타이드 공개매수 최소 조건 충족…응모 지분 66.7% 넘겨 [https://www.thebionews.net/news/articleView.html?idxno=28974](https://www.thebionews.net/news/articleView.html?idxno=28974) ●BMS, LPA1 억제제 ‘애드밀파란트’ 특발성 폐섬유증 3상 폐기능 감소 억제 [https://www.thebionews.net/news/articleView.html?idxno=28968](https://www.thebionews.net/news/articleView.html?idxno=28968) ●씨어스, ‘無 리픽싱’ 1100억 CB 발행…美 진단기관 인수·중동 사업 확대 [https://www.thebionews.net/news/articleView.html?idxno=28973](https://www.thebionews.net/news/articleView.html?idxno=28973) ●셀트리온, 日서 ‘옴리클로’ 경쟁력 집중 조명…‘퍼스트무버’ 출시 [https://www.thebionews.net/news/articleView.html?idxno=28955](https://www.thebionews.net/news/articleView.html?idxno=28955) ●BMS “알파 방출 동위원소 기반 방사성의약품 후보, GEP-NET 3상 PFS 개선” [https://www.thebionews.net/news/articleView.html?idxno=28948](https://www.thebionews.net/news/articleView.html?idxno=28948) ●지노믹트리, ‘얼리텍 방광암’ 신의료기술평가 유예 확정…‘비급여’ 검사 개시 [https://www.thebionews.net/news/articleView.html?idxno=28977](https://www.thebionews.net/news/articleView.html?idxno=28977) ●대웅제약, 재생 PC로 디지털 소외계층 지원…ESG 활동 확대 [https://www.thebionews.net/news/articleView.html?idxno=28972](https://www.thebionews.net/news/articleView.html?idxno=28972) ●GC녹십자, 헌터라제 투여 환자 ‘IgE 정밀 분석법’ 개발…국제학술지 게재 [https://www.thebionews.net/news/articleView.html?idxno=28964](https://www.thebionews.net/news/articleView.html?idxno=28964) ●바이오솔루션, ‘솔루오랄’ 기반 ISO 국제표준화 검증 연구 추진 [https://www.thebionews.net/news/articleView.html?idxno=28962](https://www.thebionews.net/news/articleView.html?idxno=28962) ●HLB바이오스텝, 50억원 규모 AI-NAMs 국책과제 참여 [https://www.thebionews.net/news/articleView.html?idxno=28961](https://www.thebionews.net/news/articleView.html?idxno=28961) ●지씨씨엘, LabConnect와 글로벌 임상시험 협력 확대 [https://www.thebionews.net/news/articleView.html?idxno=28967](https://www.thebionews.net/news/articleView.html?idxno=28967) ●Korean Researchers: Autoimmune disease patients with drooping eyelids should suspect myasthenia gravis [https://www.thebionews.net/news/articleView.html?idxno=28983](https://www.thebionews.net/news/articleView.html?idxno=28983) ●MSD Korea to roll out anti-pd-1 immunotherapy ‘Keytruda SC injection’ in Korea in October [https://www.thebionews.net/news/articleView.html?idxno=28982](https://www.thebionews.net/news/articleView.html?idxno=28982) ●APITBIO out-licenses L1CAM-targeted ‘ADC antibody’ to Mother’s Pharmaceutical, collecting KRW 2.65 billion upfront payment [https://www.thebionews.net/news/articleView.html?idxno=28981](https://www.thebionews.net/news/articleView.html?idxno=28981) ●Celltrion wins consecutive tenders for high-profit new product lines in non-EU5 European markets [https://www.thebionews.net/news/articleView.html?idxno=28980](https://www.thebionews.net/news/articleView.html?idxno=28980) ●Dong-A ST and Galux join forces on joint research for AI antibody design-based ADC novel drug [https://www.thebionews.net/news/articleView.html?idxno=28979](https://www.thebionews.net/news/articleView.html?idxno=28979) ●ENCell inks MOU on ‘stem cell regenerative medicine’ with local Osaka, Japan clinic [https://www.thebionews.net/news/articleView.html?idxno=28978](https://www.thebionews.net/news/articleView.html?idxno=28978) *제약바이오 10월 13일 아침 유튜브 라디오 뉴스(매일 아침 업로드) [https://www.youtube.com/watch?v=D5eawLLQoo8](https://www.youtube.com/watch?v=D5eawLLQoo8)